Description
Inspire Medical Systems’ $860 Million Revenue Outlook — A Tough Test for Its Recovery!
Inspire Medical Systems, Inc. reported third quarter 2026 results reflecting a 7.9% year-over-year revenue decline to $206.7 million, yet showing a modest 3% sequential increase from the prior quarter. The U.S. market outperformed, offsetting international weakness, particularly due to destocking in Germany, which contributed to the first international revenue contraction since early 2025. Gross margin improved slightly to 86%, primarily driven by a favorable mix shift toward the higher-margin Inspire V device. Operating expenses rose $23.5 million year-over-year, largely related to $24.1 million in restructuring charges from Project Horizon and $7 million in legal settlement expenses. Adjusted operating expenses declined modestly to $176 million from $181.8 million year-over-year, but operating loss widened to $28.7 million versus income of $9.6 million in the year-ago period. Adjusted operating income fell to $1.9 million from $10.9 million. Adjusted EBITDA margin declined 130 basis points to 18.3%.



